The Medicines Company (NASDAQ:MDCO) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1.13 by 8 Brokerage Firm. 7 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating.
Other Equity analysts have also commented on the company shares. Cowen & Company initiates coverage on The Medicines Company (NASDAQ:MDCO). According to the latest information available, the shares are now rated Outperform by the analysts at the agency. The rating by the firm was issued on May 5, 2016.
The Medicines Company (NASDAQ:MDCO): 7 Analyst have given the stock of The Medicines Company (NASDAQ:MDCO) a near short term price target of $49.29. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $8.22. The higher price target estimate is at $65 while the lower price estimates are fixed at $41.
The Medicines Company (NASDAQ:MDCO) witnessed a decline in the market cap on Tuesday as its shares dropped 3.78% or 1.31 points. After the session commenced at $34.7, the stock reached the higher end at $35.13 while it hit a low of $33.33. With the volume soaring to 1,423,635 shares, the last trade was called at $33.37. The company has a 52-week high of $43.79. The company has a market cap of $2,338 million and there are 70,072,431 shares in outstanding. The 52-week low of the share price is $25.38.
The Medicines Company has lost 8.5% in the last five trading days and dropped 8.6% in the last 4 weeks. The Medicines Company is up 3.06% in the last 3-month period. Year-to-Date the stock performance stands at -10.63%.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.